LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global vasculitis treatment market is projected to grow to USD 517.64 million by 2021, at a CAGR of more than 4% over the forecast period.
This research report titled ‘Global Vasculitis Treatment Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.
|The global vasculitis treatment market is expected to grow at a moderate pace during the forecast period. This growth is mainly due to a promising pipeline of drug candidates mainly comprising of biologics, which are currently in the Phase III development stage. Further, special designations such as breakthrough therapy drugs hasten the development time of a drug, leading to the introduction of new drugs during the forecast period.|
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Based on the drug class, the report categorizes the global vasculitis treatment market into the following segments:
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
“Corticosteroids are a class of steroid hormones, which helps to reduce inflammation and control symptoms of fever, weakness, fatigue, and hypertension for vasculitis diseases. Currently, corticosteroids enjoy market dominance and are expected to grow swiftly through the forecast period,” says Sapna Jha, a lead analyst at Technavio for cardiovascular and metabolic disorders research.
Corticosteroids are less toxic than sustained steroid treatment at lower quantitative dosage. They also play an important role in the treatment of rheumatoid vasculitis. Corticosteroids (such as prednisone) are the first-line therapy for rheumatoid vasculitis, where the minimum dose is used for the shortest time.
Immunosuppressants are a class of drugs that suppress or reduce the strength of the body’s immune system. These agents inhibit cell growth and proliferation, decreasing immune reactions. These drugs are used to treat diseases such as lupus, psoriasis, and rheumatoid arthritis.
The immunosuppressants segment of the vasculitis treatment market is expected to grow at a slower rate compared with the corticosteroids market. The sales of immunosuppressants are likely to decline due to the introduction of novel biologics and small molecules to treat vasculitis.
Biologics are large molecules that are extracted from biological sources, such as humans, animals, or microorganisms and are manufactured biotechnologically using cutting-edge technologies. Biologics include a wide range of products such as enzymes, allergenics, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines that are used to treat various diseases.
“The biologics segment of the vasculitis treatment market is growing at a rapid pace due to the increased uptake of these drugs, especially in the developed markets such as the US and Europe. Despite their slightly higher price point, the uptake of biologics is expected to increase and obtain considerable market share,” says Sapna.
The top vendors highlighted by Technavio’s research analysts in this report are:
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
Browse Related Reports:
- Global Anti-inflammatory Therapeutics Market 2017-2021
- Global Antiemetic Drug Market 2017-2021
- Global Substance Abuse Treatment Market 2017-2021
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.